Earnings Call · Q3 FY2022·2022-11-10

Q3 22EPS +11.11%·Rev n/aQ2 22EPS +20.00%·Rev n/aQ1 22EPS +14.29%·Rev n/aQ4 21EPS +93.33%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Robert Barrow — Chief Executive Officer and Director

Schond Greenway — Chief Financial Officer

+7.9%1d on move date+2.4% vs SPY3d+17.8%5d+21.6%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access